CL2017000971A1 - Composición farmacéutica para uso en el aumento del trofismo de mucosa nasal - Google Patents
Composición farmacéutica para uso en el aumento del trofismo de mucosa nasalInfo
- Publication number
- CL2017000971A1 CL2017000971A1 CL2017000971A CL2017000971A CL2017000971A1 CL 2017000971 A1 CL2017000971 A1 CL 2017000971A1 CL 2017000971 A CL2017000971 A CL 2017000971A CL 2017000971 A CL2017000971 A CL 2017000971A CL 2017000971 A1 CL2017000971 A1 CL 2017000971A1
- Authority
- CL
- Chile
- Prior art keywords
- nasal mucosa
- trophism
- increasing
- pharmaceutical composition
- nasal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
<p>COMPOSICIÓN PARA APLICACIÓN TÓPICA, PARA USO EN EL INCREMENTO DE TROFISMO DE LA MUCOSA NASAL, QUE COMPRENDE UN ÉSTER DE VITAMINA E CON UN ÁCIDO CARBOXÍLICO DE LA FÓRMULA R-COOH, EN LA CUAL R ES UN RADICAL ALQUILO QUE TIENE 1 A 19 ÁTOMOS DE CARBONO, O UN RADICAL ALQUENILO O ALQUINILO QUE TIENE 2 A 19 ÁTOMOS DE CARBONO, Y UN VEHÍCULO ACEITOSO; ESTA COMPOSICIÓN SE PUEDE UTILIZAR PARA EL TRATAMIENTO DE RINITIS ATRÓFICA CRÓNICA Y PARA OBTENER LA REPARACIÓN DE TEJIDO DE LA MUCOSA NASAL DESPUÉS DE LA CIRUGÍA NASAL Y DE SENOS PARANASALES.</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI20141819 | 2014-10-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017000971A1 true CL2017000971A1 (es) | 2018-01-12 |
Family
ID=51951918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017000971A CL2017000971A1 (es) | 2014-10-22 | 2017-04-20 | Composición farmacéutica para uso en el aumento del trofismo de mucosa nasal |
Country Status (20)
Country | Link |
---|---|
US (1) | US10226444B2 (es) |
EP (1) | EP3209294B1 (es) |
CN (1) | CN107438429A (es) |
AU (1) | AU2015335204B2 (es) |
CA (1) | CA2965184A1 (es) |
CL (1) | CL2017000971A1 (es) |
CY (1) | CY1122289T1 (es) |
DK (1) | DK3209294T3 (es) |
EA (1) | EA033078B1 (es) |
ES (1) | ES2757349T3 (es) |
GE (1) | GEP20186863B (es) |
HR (1) | HRP20191989T1 (es) |
HU (1) | HUE047203T2 (es) |
LT (1) | LT3209294T (es) |
MX (1) | MX2017005195A (es) |
PL (1) | PL3209294T3 (es) |
PT (1) | PT3209294T (es) |
RS (1) | RS59496B1 (es) |
SI (1) | SI3209294T1 (es) |
WO (1) | WO2016062522A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3026108A1 (en) | 2016-06-10 | 2017-12-14 | Clarity Cosmetics Inc. | Non-comedogenic hair and scalp care formulations and method for use |
IT201700047210A1 (it) * | 2017-05-02 | 2018-11-02 | St Ganassini Spa Di Ricerche Biochimiche | Composizione cosmetica e/o dermatologica, e suoi usi in campo cosmetico e nel trattamento coadiuvante di patologie dermatologiche |
IT201900003515A1 (it) * | 2019-03-11 | 2020-09-11 | Gilas Sas Di Carcano Maria Grazia E C | COMPOSIZIONE DERMO-COSMETICA PER USO TOPICO, A BASE DI VITAMINA E e/o SUOI ESTERI |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4364945A (en) | 1979-12-13 | 1982-12-21 | Whittle Barry J | Nasal composition for relieving nasal distress |
US20100055152A1 (en) | 2008-08-26 | 2010-03-04 | Trutek Corporation | Antihistamine and antihistamine-like nasal application, products, and method |
IT1282778B1 (it) * | 1996-05-31 | 1998-03-31 | Giorgio Panin | Vitamina "e" acetato quale prodotto per applicazione topica |
ITMI981586A1 (it) * | 1998-07-10 | 2000-01-10 | Giorgio Panin | Vitamina e e suoi esteri per l'uso nel trattamento topico di patologie delle mucose |
IT1393056B1 (it) * | 2008-09-22 | 2012-04-11 | Bio Lo Ga Srl | Uso di vitamina e o suoi derivati per il controllo di artropodi |
US10561720B2 (en) | 2011-06-24 | 2020-02-18 | EpitoGenesis, Inc. | Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators |
FR2981273B1 (fr) * | 2011-10-14 | 2013-12-20 | Gilles Andre Yves Bhat | Nouvelle composition pour les muqueuses: tocopherol, macerat huileux de fleurs de calendula dans de l'huile de rose musquee, palmitate de retinol, ubiquinone, ascorbyl palmitate et lactobacillus |
-
2015
- 2015-10-02 EA EA201790447A patent/EA033078B1/ru not_active IP Right Cessation
- 2015-10-02 HU HUE15783971A patent/HUE047203T2/hu unknown
- 2015-10-02 CN CN201580055149.2A patent/CN107438429A/zh active Pending
- 2015-10-02 ES ES15783971T patent/ES2757349T3/es active Active
- 2015-10-02 US US15/512,755 patent/US10226444B2/en active Active
- 2015-10-02 MX MX2017005195A patent/MX2017005195A/es active IP Right Grant
- 2015-10-02 DK DK15783971T patent/DK3209294T3/da active
- 2015-10-02 SI SI201530924T patent/SI3209294T1/sl unknown
- 2015-10-02 PL PL15783971T patent/PL3209294T3/pl unknown
- 2015-10-02 LT LT15783971T patent/LT3209294T/lt unknown
- 2015-10-02 RS RS20191407A patent/RS59496B1/sr unknown
- 2015-10-02 AU AU2015335204A patent/AU2015335204B2/en active Active
- 2015-10-02 EP EP15783971.3A patent/EP3209294B1/en active Active
- 2015-10-02 WO PCT/EP2015/072796 patent/WO2016062522A1/en active Application Filing
- 2015-10-02 PT PT157839713T patent/PT3209294T/pt unknown
- 2015-10-02 CA CA2965184A patent/CA2965184A1/en not_active Abandoned
- 2015-10-02 GE GEAP201514463A patent/GEP20186863B/en unknown
-
2017
- 2017-04-20 CL CL2017000971A patent/CL2017000971A1/es unknown
-
2019
- 2019-10-08 CY CY20191101053T patent/CY1122289T1/el unknown
- 2019-11-04 HR HRP20191989TT patent/HRP20191989T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
DK3209294T3 (da) | 2019-10-28 |
CY1122289T1 (el) | 2021-01-27 |
BR112017008070A2 (pt) | 2018-02-20 |
US10226444B2 (en) | 2019-03-12 |
MX2017005195A (es) | 2017-10-04 |
EA201790447A1 (ru) | 2017-09-29 |
ES2757349T3 (es) | 2020-04-29 |
SI3209294T1 (sl) | 2019-12-31 |
WO2016062522A1 (en) | 2016-04-28 |
AU2015335204B2 (en) | 2020-10-08 |
CN107438429A (zh) | 2017-12-05 |
CA2965184A1 (en) | 2016-04-28 |
US20170290799A1 (en) | 2017-10-12 |
BR112017008070A8 (pt) | 2022-07-05 |
EP3209294B1 (en) | 2019-08-21 |
EA033078B1 (ru) | 2019-08-30 |
AU2015335204A1 (en) | 2017-04-13 |
LT3209294T (lt) | 2019-10-25 |
RS59496B1 (sr) | 2019-12-31 |
EP3209294A1 (en) | 2017-08-30 |
PT3209294T (pt) | 2019-10-08 |
HRP20191989T1 (hr) | 2020-02-07 |
GEP20186863B (en) | 2018-06-11 |
PL3209294T3 (pl) | 2020-01-31 |
HUE047203T2 (hu) | 2020-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017001893A1 (es) | Uso de prg4 como agente antiinflamatorio | |
GT201500312A (es) | Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
CL2015002164A1 (es) | Formulación combinada de dos compuesos antivirales. | |
PE20170904A1 (es) | Esteroides neuroactivos, composiciones y usos de los mismos | |
CL2015000787A1 (es) | Derivados de 1,2,4-triazina para el tratamiento de infecciones virales. | |
BR112015022047A2 (pt) | métodos para tratar câncer de bexiga | |
BR112015022545A2 (pt) | compostos de pirazolo e os usos disso | |
CL2017000533A1 (es) | Pirrolopirimidinas para uso en la infección por el virus de la gripe | |
CR20150571A (es) | Compuestos y composiciones terapéuticos | |
UY33885A (es) | Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes | |
CL2015000976A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados. | |
SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
BR112016012840A2 (pt) | Derivado de pirimidina e fonte de ácido graxo para uso no tratamento de prisão de ventre | |
BR112015024332A2 (pt) | sonda fluorescente para estanho | |
CO2019012814A2 (es) | Composición farmacéutica líquida estable | |
BR112015022162A2 (pt) | sonda fluorescente de zinco | |
CL2017000971A1 (es) | Composición farmacéutica para uso en el aumento del trofismo de mucosa nasal | |
PE20142182A1 (es) | Inhibidores de iap | |
DOP2015000176A (es) | Compuestos de azetidiniloxifenilpirrolidina | |
CL2018001221A1 (es) | Modular la expresión de apolipoproteína (a) | |
CL2016001098A1 (es) | Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales | |
CL2016001192A1 (es) | Uso de un inhibidor de dihidroorato deshidrogenasa (dhodh) para tratar enfermedades neurodegenerativas. | |
CL2012003006A1 (es) | Compuestos derivados de lactonas esteroideas insaturadas en la posicion 7(8) y sus sales y estereoisomeros farmaceuticamente aceptables; composicion farmaceutica que las comprende; y su uso para el tratamiento del cancer. | |
CL2015001446A1 (es) | Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido. | |
ECSP15050273A (es) | Formulación oral para el tratamiento de enfermedades cardiovasculares |